Skip to main content

Incyte news and events in 2026

Incyte is a biopharmaceutical organization that discovers, develops, and commercializes novel medicines. The organization focuses on therapeutic areas including oncology, inflammation, autoimmunity, dermatology, and hematology.

Public (INCY)Pharmaceutical Manufacturing5,001 to 10,000 employeesincyte.comLinkedIn

Get Incyte's live signals in Claude or ChatGPT, or by API

AskWhat changed at Incyte this week? Use Autobound signals for incyte.com.
Dated updates
75
Last event
Oct 29, 2026
Open rolesSnapshot Nov 3, 2026
13
Latest SEC filing
Oct 29, 2026

Source: Autobound Signal API · 75 signals tracked for Incyte · updated

Overview

Incyte by topic

Latest events

Latest Incyte events

  1. Earnings
    Incyte Reports $1.56 Billion Third-Quarter Revenue and Raises 2026 Sales GuidanceIncyte posted a GAAP net loss of $784.8 million for the third quarter of 2026.
  2. Launch
    Mirum Pharmaceuticals, Incyte announce FDA approval of AtebriozIncyte, in collaboration with Mirum Pharmaceuticals, received FDA approval for its Atebrioz tablets, a treatment for fibrodysplasia ossificans progressiva in patients aged 12 and older.
  3. Revenue
    Incyte stock reports 38 percent revenue growth as shares trade at USD 123.47Incyte reported Q2 2026 revenue of USD 1.67 billion, a 38% increase year-over-year.
  4. Earnings
    A Noteworthy Decision By Lee Heeson As Acquires $130K In Incyte Stock OptionsIncyte reported a gross margin of 91.79% and an EPS of 1.52.
  5. Acquisition
  6. Acquisition
  7. Acquisition
  8. News
  9. Integration
  10. In development
    Incyte Corp stock (US45337C1027): Biopharma leader in oncology therapies.Incyte Corporation is developing novel therapies in oncology and inflammation.

Showing 10 of 13 events. The Signal API returns all of them.

Get them with one API call

Signal API · MCP

Track Incyte with the Signal API

One POST /v1/companies/enrich call with incyte.com returns every signal type for Incyte, each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"incyte.com","limit":20}'

Bulk data

Need these signals for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file).

Talk to sales

Same industry

Incyte questions

What is the latest news on Incyte?
On Oct 29, 2026, quiverquant.com reported: Incyte Reports $1.56 Billion Third-Quarter Revenue and Raises 2026 Sales Guidance. This page tracks 13 news events for Incyte since Feb 11, 2026, each with a date and a source link.
What is going on with Incyte?
In the 90 days to Nov 4, 2026, Autobound tracked 3 news events, 1 10-Q filing, 2 8-K filings, 4 hiring snapshots, 14 signals for Incyte. The newest story is from Oct 29, 2026 (Earnings), reported by quiverquant.com.
Has Incyte announced any acquisitions?
The latest deal story is from Jun 10, 2026. worldpharmatoday.com reported: Incyte expands haematology portfolio with vega acquisition. The acquisitions page lists 3 deals with a source for each.
What else does Autobound track for Incyte?
Beyond news and filings, Autobound lists 50+ signals for Incyte from 4 sources: Glassdoor (15+), YouTube (15+), Website changes (14), Patents (6). See the Incyte signals page for the dated list.
Is Incyte hiring right now?
Yes. As of Nov 3, 2026, Incyte had 13 open roles, and Sales had the most with 5.

Page updated , the date of the newest row on this page.

Source. News, SEC filings (8-K, 10-K, 10-Q, Form D), hiring data and other signals (Reddit, podcasts, Glassdoor, reviews, social posts, patents, web traffic) from the Autobound Signal API.

Method. Stories are grouped when they report the same event within 14 days. Rows that do not name the company are removed. Each row links its source.

Data as of .

How this data is built →Get it from the Signal API →